Thr NEW ENGLAND JOURNAL Of MEDICINE and other clinical-trial data not within the pub. the potential risks of rosiglitazone in the treat ic domain further analyse s of data auiable to of type 2 diabe the eDa and the manufacturer would enable a t to rerfor more robust assessment of the risks of this drug ugh the Cl nd Our data suggest a cardiovascular risk associate with the us f rosiglitazone.Un re precis them to c estmates of th car dial her income nor a tax dedu kaootherpe 。 .Medica 11.We n P.Goldstein BI,Ros smtwithamprlandostgeaz ct a one oh ired gl Mo NB, N.h al dat May i8. a gowlcder foi M.ende cular fur nd e Is with rare events.stat med with of sparse data Srat Med 2004: ert P.Jo d R 02107 of the effe Bes2002.2.36 2107 in pat with htheadioa8 2001861659.20022 Endocrino and 17.1 ent from the American Heart As r 7.2003.Circulation 2003 AMd20030387-9 ter M.Van Gaal LE th Cole MA. of gl ling bu rdha Nisse SE.Wolski K.Top ion th apy in p g sul ular 1AMA2000284 etes 7 Ther 2003 3-d pr 2470 N ENGLJ MED 356:24 WWW.NEJM.ORG JUNE 14.2007 5.2016. ther uses without permissior ciety.All rights reserveT h e n e w e ng l a nd j o u r na l o f m e dic i n e 2470 n engl j med 356;24 www.nejm.org june 14, 2007 and other clinical-trial data not within the pub￾lic domain. Further analyses of data available to the FDA and the manufacturer would enable a more robust assessment of the risks of this drug. Our data suggest a cardiovascular risk associated with the use of rosiglitazone. Until more precise estimates of the cardiovascular risk of this treat￾ment can be delineated in patients with diabetes, patients and providers should carefully consider the potential risks of rosiglitazone in the treat￾ment of type 2 diabetes. Dr. Nissen reports receiving research support to perform clinical trials through the Cleveland Clinic Cardiovascular Coor￾dinating Center from Pfizer, AstraZeneca, Daiichi Sankyo, Roche, Takeda, Sanofi-Aventis, and Eli Lilly. Dr. Nissen consults for many pharmaceutical companies but requires them to do￾nate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. No other poten￾tial conflict of interest relevant to this article was reported. We thank Craig Balog for statistical programming support. REFERENCES Vamecq J, Latruffe N. Medical signifi￾cance of peroxisome proliferator-activated receptors. Lancet 1999;354:141-8. Campbell IW. The clinical signifi￾cance of PPAR gamma agonism. Curr Mol Med 2005;5:349-63. Center for Drug Evaulation and Re￾search. Approval package: Avandia (ro￾siglitazone maleate) tablets. Company: SmithKline Beecham Pharmaceuticals. Application no. 21-071. Approval date: 5/25/1999. (Accessed May 18, 2007, at http://www.fda.gov/cder/foi/nda/99/21071_ Avandia.htm.) American Diabetes Association. Com￾plications of diabetes in the United States. (Accessed May 18, 2007, at http://www. diabetes.org/diabetes-statistics/ complications.jsp.) GlaxoSmithKline. Rosiglitazone stud￾ies. (Accessed May 18, 2007, at http://ctr. gsk.co.uk/Summary/rosiglitazone/ studylist.asp.) Center for Drug Evaluation and Re￾search. Medical review(s). Application number: 021071. (Accessed May 18, 2007, at http://www.fda.gov/cder/foi/nda/99/ 21071_Avandia_medr.pdf.) Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8. [Errata, J Clin Endocrinol Metab 2001;86:1659, 2002;2:iv.] Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15. [Erratum, Diabetes 2001;24:973.] Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, in￾sulin-resistant patients with type 2 diabe￾tes. Diabetes Obes Metab 2003;5:163-70. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in pa￾tients with type 2 diabetes mellitus: a ran￾domized controlled trial. JAMA 2000;283: 1695-702. [Erratum, JAMA 2000;284: 1384.] 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin com￾pared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005;21:2029-35. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000;17:40-7. St John Sutton M, Rendell M, Dando￾na P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovas￾cular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-64. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone thera￾py in patients with inadequately con￾trolled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32. Vongthavaravat V, Wajchenberg BL, Waitman JN, et al. An international study of the effects of rosiglitazone plus sul￾phonylurea in patients with type 2 diabe￾tes. Curr Med Res Opin 2002;18:456-61. Baksi A, James RE, Zhou B, Nolan JJ. Comparison of uptitration of gliclazide with the addition of rosiglitazone to glic￾lazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol 2004;41:63-9. Barnett AH, Grant PJ, Hitman GA, et al. Rosiglitazone in Type 2 diabetes mel￾litus: an evaluation in British Indo-Asian patients. Diabet Med 2003;20:387-93. Kerenyi Z, Samer H, James R, Yan Y, Stewart M. Combination therapy with rosiglitazone and glibenclamide com￾pared with upward titration of gliben￾clamide alone in patients with type 2 dia￾betes mellitus. Diabetes Res Clin Pract 2004;63:213-23. Zhu XX, Pan CY, Li GW, et al. Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther 2003;5:33-42. The DREAM (Diabetes Reduction As- 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. sessment with ramipril and rosiglitazone Medication) Investigators. Effect of rosig￾litazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096- 105. [Erratum, Lancet 2006;368:1770.] Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. [Erratum, N Engl J Med 2007;356:1387-8.] Bradburn MJ, Deeks JJ, Berlin JA, Lo￾calio AR. Much ado about nothing: a com￾parison of the performance of meta-ana￾lytical methods with rare events. Stat Med 2007;26:53-77. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoid￾ance of continuity corrections in meta￾analysis of sparse data. Stat Med 2004;23: 1351-75. [Erratum, Stat Med 2006;25:2700.] Sutton A, Cooper N, Lambert P, Jones D, Abrams K, Sweeting M. Meta-analysis of rare and adverse event data. Pharmaco￾economics Outcomes Res 2002;2:367. Avandia (rosiglitazone maleate) tab￾lets: prescribing information. Research Triangle Park, NC: GlaxoSmithKline, 2007 (package insert). (Accessed May 18, 2007, at http://www.fda.gov/cder/foi/label/2007/ 021071s023lbl.pdf.) Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart As￾sociation and American Diabetes Associa￾tion: October 7, 2003. Circulation 2003; 108:2941-8. Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, Neubauer S. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mor￾tality in rats post-myocardial infarction. Cardiovasc Res 2003;58:632-7. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major ad￾verse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294:2581-6. El-Hage J. Peroxisome proliferator￾activated receptor (PPAR) agonists: pre- 21. 22. 23. 24. 25. 26. 27. 28. 29. The New England Journal of Medicine Downloaded from nejm.org on February 5, 2016. For personal use only. No other uses without permission. Copyright © 2007 Massachusetts Medical Society. All rights reserved